Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.

Abstract

Antibody-drug conjugates (ADC), a combination of cytotoxic drugs and antibodies, have emerged as a rising star in cancer therapy. Disitamab vedotin (RC48), a novel ADC targeting human epidermal growth factor receptor 2 (HER2), is currently being explored in a variety of malignancies. Compared with conventional HER2-targeting agents, RC48 is characterized by a wider therapeutic window and less toxicity to normal tissues. In this review, we will analyze the structural elements and mechanisms of RC48. Besides, we provide a landscape on the progression of RC48 in common malignancies, focusing on RC48 in gastric or gastroesophageal junction cancer, and a brief overview of urothelial, breast and other cancers (e.g., gynecological cancer, biliary tract cancer, non-small cell lung cancer and myometrial invasive bladder cancer). Finally, we will also discuss future challenges in the development of RC48 and future directions to improve efficacy.

• Authors: Yixuan Hu, Yinxing Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 58 Issue 10 Pg. 491-507 (Oct 2022) ISSN: 1699-3993 [Print] Spain
• PMID: 36305543 (Publication Type: Review, Journal Article)
• Copyright: Copyright 2022 Clarivate.

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• ERBB2 protein, human
• Immunoconjugates
• Receptor, ErbB-2

Topics

• Humans
• Antibodies, Monoclonal
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Immunoconjugates (therapeutic use)
• Lung Neoplasms (drug therapy)
• Receptor, ErbB-2 (metabolism)
• Stomach Neoplasms (drug therapy)